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Abstract
Background: The technique most frequently used to genotype HCV is quantitative RT-PCR. This technique is
unable to provide an accurate genotype/subtype for many samples; we decided to develop an in-house method
with the goal of accurately identifying the genotype of all samples. As a Belgium National Centre of reference for
hepatitis, we developed in-house sequencing not only for 5’UTR and core regions starting from VERSANT LiPA
amplicons but also for NS5B regions. The sequencing of VERSANT LiPA amplicons might be useful for many
laboratories worldwide using the VERSANT LiPA assay to overcome undetermined results.
Methods: 100 samples from Hepatitis C virus infected patients analysed by the VERSANT HCV Genotype 2.0 LiPA
Assay covering frequent HCV types and subtypes were included in this study. NS5B, 5’UTR and Core home-made
sequencing were then performed on these samples. The sequences obtained were compared with the HCV
genomic BLAST bank.
Results: All the samples were characterised by the VERSANT LiPA assay (8 G1a, 17 G1b, 6 G2, 11 G3, 13 G4, and 10 G6).
It was not possible to discriminate between G6 and G1 by the VERSANT LiPA assay for 8 samples and 27 had an
undetermined genotype. Forty-one samples were sequenced for the three regions: NS5B, 5’UTR and Core. Twenty-
three samples were sequenced for two regions: 5′ UTR and Core and 36 samples were sequenced only for NS5B. Of
the 100 samples included, 64 samples were analysed for 5’UTR and Core sequencing and 79 samples were analysed for
NS5B sequencing. The global agreement between VERSANT LiPA assay and sequencing was greater than 95%.
Conclusions: In this study, we describe a new, original method to confirm HCV genotypes of samples not
discriminated by a commercial assay, using amplicons already obtained by the screening method, here the VERSANT
LiPA assay. This method thus saves one step if a confirmation assay is needed and might be of usefulness for many
laboratories worldwide performing VERSANT LiPA assay in particular.
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Background
Due to its high rate of mutation, hepatitis C virus (HCV)
forms viral quasispecies, classified based on the highly
variable regions in the envelope protein and nonstruc-
tural 5B protein (NS5B). As a result of this large genetic
variability, seven genotypes and more than 67 subtypes
have been identified [1]. The global repartition of geno-
types varies across countries but genotype 1 is the most
common with more than 45% worldwide, followed by
genotype 3 [2]. In Belgium, a recent publication showed
the same distribution of HCV genotypes with 53.6% of
genotype 1 (31.6% subtype 1b and 19.7% subtype 1a)
followed by genotype 3 with 22.0% [3].
HCV genotyping is part of the evaluation of newly di-
agnosed patients and has always been important in guid-
ing treatment [4]. In the last EASL recommendations for
the treatment of hepatitis C [5], identification of HCV
genotype remains an essential consideration. Since the
development of pan-genotype direct acting agents
(DAA), correct identification of the genotype is import-
ant to guide the choice of the DAA combination and the
duration of the treatment. Indeed, several studies have
shown that a misclassification of the HCV genotype can
lead to therapeutic failure. Starace et al. showed that
14.9% of DAA failure are related to a genotyping error
[6] and Di Maio et al. report that 6/197 (3%) of DAA-
failing patients and in particular 4/7 non responders to a
DAA INF-free regimen were impacted on a wrong geno-
type assignment [7].
In addition to its impact on the choice of treatment,
genotyping is also important for epidemiological infor-
mation and the development of cost-effectiveness na-
tional treatment strategies [8].
Considering that genotype is a key element in the
management of patients infected with hepatitis c virus,
the determination of the genotype is recommended but
in recent guidelines of the European Association of the
Study of the Liver (EASL) published in 2018 [5], no rec-
ommendation was made on the assay to use. It is only
mentioned that “the most widely used method is based
on reverse hybridization with the line probe assay” and
that “a kit based on deep sequencing will soon be avail-
able” [5]. Guidelines also mentioned that genotype as-
says should target the 5′ untranslated region (5’UTR)
and another region for identification of the genotype 1
subtype (1a or 1b), generally the core or the NS5B re-
gion [5]. In the EASL 2018 guidelines [5], it is recom-
mended that genotypes 1(G1), 2 (G2), 3 (G3), 4 (G4), 5
(G5) and 6 (G6) and the subtypes a and b of genotype 1
(G1a and G1b) should be distinguished. Therefore, we
focused this work only on subtyping G1, no analysis was
done for the subtype of the other genotypes.
As mentioned above, the technique most frequently
used to genotype HCV is reverse transcriptase PCR (RT-
PCR), with VERSANT HCV Genotype 2.0 Line Probe
Assay (VERSANT LiPA; Healthcare SIEMENS, Munich,
Germany), the other most widely used commercial geno-
typing assays is the Abbott RealTime HCV Genotype II
(Abbott GTII; Abbott, Illinois, USA) [8].
The two commercial assays detect genotypes 1 to 6
and subtypes 1a and 1b. The Abbott GTII assay targets
the 5’UTR region for classification of HCV genotypes
and the NS5B region for detection of the genotype 1
subtypes. The VERSANT LiPA assay targets the 5’UTR
region for the genotype and the core region for subtype
1a and 1b.
These commercial assays have shown some limitations
that must be kept in mind. The first limitation is the
percentage of non-subtypable G1. Some publications re-
ported that Genotype 1 subtypes were not identified by
the Abbott GTII assay in 3.7 to 15.9% of cases (with a
mean of 8.5%) [9–11] and in 2.2 to 7.4% of cases with
the VERSANT LiPA assay [10]. Other limitations are
that the commercial assays are not always able to differ-
entiate between G6 and G1b [10], coinfection [12] or re-
combination of HCV genotypes [13]. In addition, an
undetermined result is obtained for some samples. In
our experience, over a 2-year period (2016–2017) and
678 genotype analyses performed with the VERSANT
LiPA assay in the laboratory at the Cliniques Universi-
taires Saint-Luc, a tertiary hospital, out of a total of 276
G1b samples, 6% (17/276) could not be distinguished
from genotype 6. In addition 3.5% (24/678) of analyzed
samples gave an undetermined genotype during the
same period. Noppornpanth et al. reported similar re-
sults in their study [14].
Because the VERSANT LiPA was unable to provide an
accurate genotype/subtype for a significant number of
samples, we decided to develop an in-house method
with the goal of accurately identifying the genotype for
all tested samples. As a National Centre of reference for
hepatitis in Belgium, we decided to develop a home-
brewed sequencing assay for 5’UTR and core regions
starting from VERSANT LiPA amplicons. To our know-
ledge, this is the first description of the sequencing of
VERSANT LiPA amplicons that might be useful for
many laboratories worldwide using the VERSANT LiPA
to genotype samples with undetermined results. We also
decided to develop in-house sequencing assay for NS5B
region because it is well recognized that NS5B is the
most discriminant region for HCV genotyping.
Methods
Samples
In this retrospective study, we evaluated the determin-
ation of hepatitis C genotype of samples from HCV in-
fected patients. In order to make the comparison of the
sequencing of the 5’UTR, Core and NS5B regions we
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select 100 genotype pre-characterized samples from
HCV infected patients.
Samples were selected to obtain at least 5 samples per
genotype or G1 subtype except for G5 and G7, respon-
sible for less than 2% of HCV infection in Belgium [3].
We also added undetermined VERSANT LiPA samples
to challenge the sequencing assays.
All samples were received at the laboratory of Cliniques
universitaires Saint-Luc for routine HCV genotyping and
initially genotyped using our standard technique, the
VERSANT HCV Genotype 2.0 Assay (VERSANT LiPA)
(Siemens Healthcare Diagnostics, Erlangen, Germany). Ac-
cording to the LiPA protocol, the efficacy of the RT-PCR is
not optimal for viral load below 2000 IU/mL, consequently,
all analysed samples had a viral load above this limit.
No patient identifiers were included in the dataset
used for this analysis. The study was approved by the
local ethical committee.
VERSANT HCV genotype 2.0 assay (LiPA)
After RNA extraction from plasma and RT-PCR of the
5’UTR and core regions of the HCV genome according to
the manufacturer’s instructions, amplicons were obtained
for 5’UTR and core regions. DNA products were hybridised
with specific probes immobilised on a nitrocellulose mem-
brane according to the manufacturer’s instructions. The hy-
bridisation profile of the sample enables the genotype to be
identified. The 5’UTR region is used for identification of
the genotype and the core regions to specify the subtype of
genotype 1. This assay can identify 6 genotypes and 18 sub-
types (1a, 1b, 2a or c, 2b, 3a, 3b, 3c, 4a/c/d, 4b, 4e, 4f, 4 h,
5a, 6a or b). If the hybridisation profile was insufficient to
identify a specific genotype, the genotype was reported as
undetermined. When the hybridisation profile of the core
region was insufficient, genotype 1 could not be discrimi-
nated from genotype 6.
HCV RNA extraction and amplification of the HCV
NS5B region
HCV RNA was extracted from a 200 μL of EDTA
plasma sample with the Roche MagNA pure compact
Nucleic Acid isolation kit I using the MagNA pure com-
pact instrument (Roche Diagnostics, Basel, Switzerland),
according to the manufacturer’s instructions. The
extracted nucleic acid was eluted using 50 μL of elution
buffer, HCV RNA was denaturised and reverse-
transcribed. NS5B amplification was achieved using a
KOD Hot Start DNA polymerase (Merck, Darmstadt,
Germany) and specific NS5B amplification-FOR and
REV primers describe by Margall et al. [15] (Table 1).
The PCR was conducted using the following protocol: 2
min at 95 °C, 40 cycles of 20 s at 95 °C, 10 s at 60 °C and
5 s at 70 °C, and finally 5 min at 70 °C.
All the PCR products were confirmed using electro-
phoresis on agarose gel. The expected amplicon size was
367 bp. All the PCR products were purified using the
QIAquick PCR purification Kit according to the manufac-
turer’s instructions (Qiagen GmbH, Hilden, Germany). To
optimise the sequencing, all the PCR products were di-
luted to a 10 ng/μL concentration with elution buffer (EB).
The concentration of DNA was measured using the spec-
trophotometer GeneQuantII (Biochrom, Holliston, USA).
Sequencing of 5’UTR, core and NS5B regions
The sequencing was based on the Sanger technique and
the BigDye X Terminator (Life Technologies, Carlsbad,
California, USA) was used. The different primers used
are listed in Table 1. The primers used for sequencing of
5’UTR and core regions were designed in our laboratory.
The primers used for sequencing of NS5B regions were
describe by Margall et al. [15]. The sequencing protocol
was as follows: 2 min at 96 °C, 40 cycles of 20 s at 96 °C,
10 s at 50 °C and 5 s at 60 °C, and finally the sequences
were maintained at 40 °C.
For NS5B sequencing, PCR products from EDTA plasma
diluted in EB buffer were used. For core and 5′-UTR, the
products obtained from the VERSANT HCV Genotype 2.0
Assay were used. One microlitre of amplicon was diluted
with 9 μL of reaction mix (4.5 μL DEPX H2O, 1.5 μL se-
quencing buffer 5x, 1 μL RRmix and 2 μL of sequencing
primer). The DNA sequence was determined using the
ABI3500 Genetic Analyzer (Thermo Fisher Scientific-
Applied Biosystems, Foster City, California, USA).
The sequences obtained were read and aligned with
the Geneious Prime® 2019.0.1 (Biomatters Ltd., Auck-
land, New Zealand). A consensus sequence was gener-
ated for each sample and compared with the HCV
genomic Basic Local Alignment Search Tool (BLAST)
bank for determination of the HCV genotype and sub-
type. A threshold for similarity of minimum 85% was
used to consider the genotype or subtype.
Phylogenetic analysis
Nucleotide sequences were aligned with reference se-
quences available in GenBank using Geneious Prime®
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2019.0.1. A phylogenetic tree was reconstructed using
the maximum likelihood (ML) approach implemented in
PhyML 3.0 [16] with automatic selection of the best fit
evolutionary model of DNA substitution (GTR + G + I)
using the Akaike information criterion (AIC). Branch
support was obtained by approximate likelihood-ratio
test (aLRT, SH-like) [17], a likelihood based alternative
to the computationally intensive bootstrapping.
A second phylogenetic tree was constructed using
Neighbor-joining method with genetic distances com-
puted by Tamura Nei mode. Using Geneious Prime®
2019.0.1.
Statistical analysis
Statistical analysis was performed using MedCalc for
Windows, version 18.6 (MedCalc Software, Ostend,
Belgium). The kappa statistic was used to estimate the
agreement between the different genotyping assays.
Ethics approval
The study was approved by the local ethical committee
“Comité d’Ethique Hospitalo-Facultaire Saint-Luc –
UCL” under number 2018/30AVR/197.
Results
Characteristics of analysed samples
One hundred samples included in the study were ana-
lysed by the VERSANT LiPA assay and gave the follow-
ing results: 25 G1 (8 G1a, 17 G1b), 6 G2, 11 G3, 13 G4,
and 10 G6. It was not possible to discriminate between
G1 and G6 by the VERSANT LiPA assay for 8 samples
and 27 had an undetermined genotype with this assay.
A total of 100 patients were included in the study
among which 41 were sequenced for the 3 regions,
5’UTR, core and NS5B, 23 patients were sequenced for
5’UTR and Core regions and 36 were sequenced for
NS5B region only. This repartition was made in function
of the available matrix.
Genotype and subtype analysis
VERSANT LiPA assay compared to 5’UTR region sequencing
Out of the 64 VERSANT LiPA amplicons included, 49 se-
quences could be analysed for the 5’UTR region. Out of
these 49 sequences, 40 (81.6%) had the same genotypes
identified with the VERSANT LiPA assay (Table 2): 15
samples were identified as G1, 5 samples as G2, 7 as G3,
10 as G4 and 3 as G6. Out of the 15 samples identified as
G1 by the two assays, the G1 subtype identified was iden-
tical for 9 samples (2 G1a and 7 G1b). For the determin-
ation of the type and G1 subtype, the kappa coefficient
was 0.94 and 0.82 respectively, which means that the
strength of agreement between VERSANT LiPA assay and
5’UTR region sequencing was almost in perfect agree-
ment. Of 7 samples for which discrimination between
G1b and G6 was not possible with the VERSANT LiPA
assay, 1 was identified as G6 by 5’UTR sequencing, 5 as
G1b and 1 sample remained undetermined. Of the 9 sam-
ples identified as G6 by the VERSANT LiPA assay, 3 were
also identified as G6 by 5’UTR sequencing, 1 as G1b and 4
were undetermined (Table 3).
All discordant samples are detailed in the Table 4.
VERSANT LiPA assay compared to core region sequencing
Out of the 64 VERSANT LiPA amplicons included, 56
sequences could be analysed for the Core region. Out of
these 56 sequences, 44 (78.6%) had the same genotype
identified with the VERSANT LiPA assay (Table 2): 15
samples were identified as G1, 5 samples as G2, 6 as G3,
10 as G4 and 8 as G6. Out of the 15 G1 samples, both
assays revealed the same for all samples (3 G1a and 12
G1b). For the determination of the type and G1 subtype,
the kappa coefficient was 0.92 and 1 respectively, which
means that the strength of agreement between VER-
SANT LiPA assay and core region sequencing was
almost in perfect agreement.
Of 7 samples for which discrimination between G1b
and G6 was not possible with the VERSANT LiPA assay,
2 were identified as G6 by Core sequencing and 5 as
Table 2 Concordance for HCV genotype and subtype determination with the different genotyping assays – VERSANT LiPA assay as reference
Genotype Concordance percentage: VERSANT LiPA assay vs
5’UTR sequencing (n) Core sequencing (n) NS5B sequencing (n)
G1 100% (15/15) 94% (15/16) 92% (12/13)
G1a 40% (2/5) 75% (3/4) 100% (3/3)
G1b 70% (7/10) 100% (12/12) 90% (9/10)
G2 100% (5/5) 100% (5/5) 100% (6/6)
G3 100% (7/7) 86% (6/7) 100% (7/7)
G4 91% (10/11) 100% (10/10) 100% (8/8)
G6 60% (3/5) 100% (8/8) 100% (3/3)
G1 or 6 100% (6/6) 100% (7/7) 100% (5/5)
G Genotype
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VERSANT LiPA assay 5’UTR sequencing CORE sequencing NS5B sequencing
HCV066 1b or 6 NI 1b 1
HCV067 1b or 6 1b 1b 1b
HCV068 1b or 6 1b 1b 1b
HCV069 1b or 6 1b 1b NR
HCV070 1b or 6 1b 6 6
HCV071 1b or 6 1b 1b NI
HCV072 1b or 6 6 6 NR
HCV073 1a or 6 NR NR 1
NI sequence not interpretable, NR not realised (short sample)




VERSANT LiPA assay 5’UTR sequencing CORE sequencing NS5B sequencing
HCV001 1a 1a/b 1a 1a
HCV003 1a 1a/b 1a NR
HCV004 1a 1b 6 NR
HCV010 1b 1a/b 1b 1b
HCV011 1b 1a/b 1b 1b
HCV013 1b NI 1b 6
HCV020 1b 1 1b NR
HCV037 3a 3 3/2 NR
HCV046 4 4/3 4 NR
HCV060 6 1b 6 NR
HCV062 6a/6b 1b/6 6 NR
HCV066 1b* NI 1b 1
HCV067 1b* 1b 1b 1b
HCV068 1b* 1b 1b 1b
HCV069 1b* 1b 1b NR
HCV070 1b* 1b 6 6
HCV071 1b* 1b 1b NI
HCV072 1b* 6 6 PA
HCV073 1a ou 6 NR NR 1
HCV075 ID 1/3/6 6 1b
HCV076 ID 1b 1b 6
HCV001 1a 1a/b 1a 1a
HCV003 1a 1a/b 1a NR
HCV004 1a 1b 6 NR
HCV010 1b 1a/b 1b 1b
HCV011 1b 1a/b 1b 1b
HCV013 1b NI 1b 6
NI sequence not interpretable, NR not realised (short sample), UND Genotype undetermined by the VERSANT LiPA assay
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genotype 1b. Of the 9 samples identified as G6 by the
VERSANT LiPA assay, 8 were also identified as G6 with
core sequencing and 1 was undetermined (Table 3).
All discordant samples are detailed in the Table 4.
VERSANT LiPA genotyping compared to NS5B region
sequencing
Out of the 77 EDTA samples analysed for the NS5B
region only 69 (89,6%) were correctly amplified and
used in this comparison. Thirty-six (52,2%) samples
had the same genotype identified with the VERSANT
LiPA assay: 12 samples were identified as G1, 6 as
G2, 7 as G3, 8 as G4 and 3 as G6. Out of the 12
samples identified as G1 by the two assays, the G1
subtype identified is the same for all the samples (3
G1a and 9 G1b). For the determination of the type
and G1 subtype, the kappa coefficient was 0.94 and 1
respectively, which means that the strength of agree-
ment between VERSANT LiPA assay and NS5B re-
gion sequencing was almost in perfect agreement.
Of 5 samples for which discrimination between G1
and G6 was not possible by the VERSANT LiPA assay, 1
was identified as G6 by NS5B sequencing, 2 as G1b and
2 as G1 without subtype information. Of the 3 samples
identified as G6 by the VERSANT LiPA assay, all were
confirmed as G6 with NS5B sequencing.
All discordant samples are detailed in the Table 4.
NS5B region sequencing compared with the other assays
Knowing that the sequencing of the NS5B region is the
genotyping method currently considered to be the gold
standard, we have presented the results also according
to the genotype given by this sequencing. Table 5 allows
us to assess the concordance of the different assays. In
our sample cohort, we can see that the agreement be-
tween the different assays is 100% for G2, G3 and G4.
The percentage of agreement decreases for G1 and G6.
For G1, the worst agreement is reported for the
VERSANT LiPA assay with a percentage of 75%
followed by the sequencing of the 5′ UTR region
with a percentage of 85.7%. The sequencing of the
core region shows the best agreement with a percent-
age of 89%. We can notice that this mismatch is due
to the misidentification of the G1b for all the tests (3
samples out of 6 correctly identified with the sequen-
cing of the 5′ UTR region, 9 samples out of 11 with
the VERSANT LiPA and 6 samples out of 7 with the
sequencing of the core region).
Phylogenetic analysis
Phylogenetic trees were build using 47 reference se-
quences and 45 sample sequences for the 5’UTR region,
50 sample sequences for the Core region and 35 sample
sequences for the NS5B region. Maximum likelihood
tree (Figs. 1, 2 and 3) showed that genotyping based on
the 5’UTR sequencing was the less discriminant com-
pared with genotyping based on Core or NS5B sequen-
cing. Indeed, when we look at the 5′ UTR tree (Fig. 1),
we can see that the genotypes mix mainly with regard to
G1a, G1b and G6. We can also notice that G4 was split
into two groups. On the contrary, the trees of the Core
region (Fig. 2) and NS5B region (Fig. 3) shown a very
good grouping of the different genotypes, both for the
reference sequences and the sample sequences. This dis-
crimination even extends to the subtype (clearly visible
for the G4) for the NS5B tree (Fig. 3).
Trees obtained from Neighbor-joining method showed
similar results (date not shown).
Discussion
Following the arrival of the newer approved anti-HCV
pangenotypic DAAs, one might think that genotype de-
termination is of little use, however, according to the last
EASL recommendations [5] for the Treatment of Hepa-
titis C published in 2018, determining the HCV geno-
type, including subtypes 1a and 1b, remains useful when
Table 5 Concordance for HCV genotype and subtype determination with the different genotyping assays – NS5B sequencing as
reference
NS5B Concordance percentage: NS5B sequencing vs
5’UTR sequencing (n) Core sequencing (n) VERSANT LiPA assay (n)
G1 85,7% (6/7) 89% (8/9) 75% (12/16)
G1a 0% (0/1) 100% (1/1) 100% (3/3)
G1b 50% (3/6) 86% (6/7) 82% (9/11)
G2 100% (6/6) 100% (5/5) 100% (6/6)
G3 100% (3/3) 100% (3/3) 100% (7/7)
G4 100% (6/6) 100% (5/5) 100% (8/8)
G6 0% (0/2) 60% (3/5) 60% (3/5)
G2k/1b 0% (0/1) 0% (0/1) –
G Genotype
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choosing a treatment and its duration. Assays that are
recommended for genotyping are those that can discrim-
inate genotyping/subtyping with amplification of the
5’UTR region plus one other region, usually the NS5B or
core region. Commercial assays perform these goals with
a globally good performance [18]. The two most fre-
quently used commercial assays are the VERSANT LiPA
and GII Abbott assays. Regardless of the assay used, dis-
criminating between genotype 6 and genotype/subtype
1a and 1b remains a challenge. In approximately 5% of
samples, this distinction cannot be made [10]. For the
GII Abbott assay, more than 90% of genotypes and sub-
types would be correctly identified [10, 11, 18, 19] and
Mallory et al. [11] recommended to confirm samples
with coinfected genotypes or an unkown G1 subtype
with another method, representing 5.5% of samples in-
cluded in their cohort. The VERSANT LiPA failed to
distinguish the subtype of genotype 1b in 17 samples
(6%) of 276 samples over a 2-year period in our hospital.
During the same period, 24 (3.5%) of 678 genotypes per-
formed could not be determined. These percentages are
concordant with the literature [14, 19–21].
In this study, we investigated the accuracy of the VER-
SANT LiPA assay for genotyping HCV with sequencing
of three different regions of the HCV: the 5’UTR, the
core region and the NS5B region. Sequencing of the
NS5B region was performed on EDTA plasma samples
while sequencing of the 5’UTR and core regions was
performed from VERSANT LiPA amplicons. One hun-
dred samples were included and all were pre-genotyped
by the VERSANT LiPA assay. Sixty-four VERSANT
LiPA amplicons were sequenced for 5’UTR and core re-
gions. Seventy-seven EDTA plasma samples were se-
quenced for the NS5B region. We showed that the
Fig. 1 Maximum likelihood phylogenetic tree (ML) of the 5’UTR gene sequences from 47 reference sequences and 45 sample sequences. The
tree branches, including the outer circle, are colored according to the HCV types and subtypes 1a and 1b. The tree scale refers to the number of
nucleotide substitutions per site. ML tree showed that genotyping based on 5’UTR sequencing was the least discriminating showing erroneous
clustering mainly with respect to G1a (in green in the figure), G1b (in blue) and G6 (in brown). We can also observe that G4 (in light blue) is
divided into 2 groups
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amplification rate was the lowest for NS5B, only 69 sam-
ples out of 77 (89,6%) were correctly amplified, this low
rate of amplification is probably explained by the fact that
most of the samples included in this study were compli-
cated samples. In addition, matrices used have undergone
higher freeze-thaw cycles than a routine cohort. It is well
known that the NS5B region is less preserved than the
Core or 5’UTR region but in contrast, it allows the most
correct HCV genotype determination [22].
The HCV genotypic distribution of the samples in-
cluded in the study was not representative of the HCV
genotypic prevalence in Belgium; indeed the samples in-
cluded were preselected to have a mix of the different
genotypes found in our country.
When taking the VERSANT LiPA assay as a reference,
we showed that the global accuracy for genotyping was
high if undetermined genotypes were not taken into ac-
count; globally, accuracy was greater than 95%. If we
take the sequencing of the NS5B region as reference, this
global accuracy fell. However, sequencing enabled dis-
crimination of all the samples (27/100) that were not
identified by the VERSANT LiPA assay. Genotype/sub-
type 1a, 1b and 6 were accurately identified in more than
95% of samples with sequenced Core and NS5B regions,
but this percentage was lower for 5’UTR region sequen-
cing with accurate identification in only 69% of samples.
These values are concordant with those reported in the
literature [10, 11, 14, 18–21]. Indeed, it is well estab-
lished that sequencing of the 5’UTR region of HCV is
not sufficient to distinguish between genotype/subtypes
1a, 1b and 6 [9].
Few studies have shown that the genotyping challenge
is higher for the subtyping of G1a and 1b [23–25].
Knowing that G1a and G1b are associated with different
rates of resistance-associated variants and different re-
sponses to DAAs, correct identification of G1 subtype
Fig. 2 Maximum Likelihood (ML) phylogenetic tree of the Core gene sequences from 47 reference sequences and 50 sample sequences. The tree
branches, including the outer circle, are colored according to the HCV types and subtypes 1a and 1b. The tree scale refers to the number of
nucleotide substitutions per site. The ML tree of the Core region showed a very good grouping of the different genotypes, for reference and
sample sequences
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remains important and may have implications for re-
sponses rate to DAAs [25, 26].
Based on the literature and our own data, we would be
very cautious in interpreting HCV genotyping result if
the Abbott test is used in the first line and we would not
hesitate to do the NS5B sequencing assay as a confirm-
ation test. When using the VERSANT LiPA assay, G1
subtyping without core region information should be
confirmed by a sequencing method. All undetermined
results must also be sequenced. HCV genotyping results
that would be confirmed represent approximately 5% in
our cohort. Taking in account the cost of these confirm-
ation tests, we report here an assay that uses VERSANT
LiPA amplicons already available allowing a significant
saving of costs, workload, set up of a RT-PCR steps and
would not require extra plasma samples.
We would therefore recommend the sequencing of the
core region when the VERSANT LiPA amplicons are
available and the sequencing of the NS5B region starting
from plasma sample. As shown in the analysis of phylo-
genetic trees, the sequencing of the NS5B region allows
for better discrimination of HCV genotyping and sub-
typing, the sequencing of the core region gives results
close to those of NS5B sequencing, the 5′ UTR region is
the least recommended of the 3 regions due to low dis-
crimination. Homemade or commercial Sanger sequen-
cing or Next Generation sequencing assays should be
performed at least in specialized laboratories such as
National Reference Centers.
Conclusions
The high genetic variability of HCV makes it a challenge
to correctly determine genotype and subtypes using
commercial assays. For undetermined samples, supple-
mentary testing is required. Even if no G5 and G7 were
included in our study, we describe new and original
Fig. 3 Maximum Likelihood (ML) phylogenetic tree of the NS5B gene sequences from 47 reference sequences and 35 sample sequences. The
tree branches, including the outer circle, are colored according to the HCV types and subtypes 1a and 1b. The tree scale refers to the number of
nucleotide substitutions per site. The ML tree of the NS5B region showed the best grouping of the different genotypes, for reference and sample
sequences. This discrimination even extended to the subtype for instance for G4 in light blue in the Figure
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methods of sequencing 5’UTR and Core regions to con-
firm HCV genotypes not discriminated by a commercial
assay, in particular by using amplicons already obtained
by the VERSANT HCV Genotype 2.0 Line Probe Assay.
This method thus saves costs and workload of RT-PCR
steps if a confirmation assay is needed and might be of
usefulness for overcoming the problem of undetermined
results in many laboratories worldwide performing the
VERSANT LiPA assay.
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